Cytosorbents (NASDAQ:CTSO) Earns Buy Rating from D. Boral Capital

Key Points

• Cytosorbents' stock has been restated with a "buy" rating by D. Boral Capital, with a price target of $10.00.
• The company reported a quarterly EPS of ($0.05), exceeding expectations, while revenue was slightly below consensus at $9.62 million.
• Cytosorbents has seen significant institutional investment, with various hedge funds raising their stakes in recent quarters, indicating increasing confidence in the company's prospects.

Cytosorbents (NASDAQ:CTSO - Get Free Report)'s stock had its "buy" rating restated by investment analysts at D. Boral Capital in a report released on Tuesday,Benzinga reports. They presently have a $10.00 price target on the medical research company's stock.

Separately, Wall Street Zen assumed coverage on Cytosorbents in a research note on Wednesday, May 21st. They set a "hold" rating for the company. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Cytosorbents currently has a consensus rating of "Moderate Buy" and a consensus target price of $5.50.

Cytosorbents Price Performance

NASDAQ CTSO opened at $0.89 on Tuesday. Cytosorbents has a one year low of $0.71 and a one year high of $1.61. The stock has a 50-day moving average of $0.99 and a 200 day moving average of $1.01. The company has a market capitalization of $55.73 million, a price-to-earnings ratio of -5.22 and a beta of 1.28. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.96 and a current ratio of 2.34.

Cytosorbents (NASDAQ:CTSO - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.07) by $0.02. The company had revenue of $9.62 million during the quarter, compared to the consensus estimate of $9.79 million. Cytosorbents had a negative return on equity of 111.97% and a negative net margin of 25.58%. On average, sell-side analysts forecast that Cytosorbents will post -0.3 EPS for the current year.

Institutional Investors Weigh In On Cytosorbents

A number of hedge funds have recently made changes to their positions in CTSO. Northern Trust Corp raised its stake in Cytosorbents by 22.3% in the fourth quarter. Northern Trust Corp now owns 91,560 shares of the medical research company's stock valued at $83,000 after buying an additional 16,701 shares during the last quarter. Millennium Management LLC purchased a new position in shares of Cytosorbents in the fourth quarter worth about $30,000. Key Client Fiduciary Advisors LLC raised its stake in shares of Cytosorbents by 127.0% in the first quarter. Key Client Fiduciary Advisors LLC now owns 78,457 shares of the medical research company's stock worth $78,000 after purchasing an additional 43,900 shares during the last quarter. Skylands Capital LLC raised its stake in shares of Cytosorbents by 7.9% in the first quarter. Skylands Capital LLC now owns 3,002,702 shares of the medical research company's stock worth $3,003,000 after purchasing an additional 221,080 shares during the last quarter. Finally, CM Management LLC raised its stake in shares of Cytosorbents by 36.3% in the first quarter. CM Management LLC now owns 954,076 shares of the medical research company's stock worth $954,000 after purchasing an additional 254,076 shares during the last quarter. 32.87% of the stock is currently owned by hedge funds and other institutional investors.

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.